HOW DOES IT WORK?
"ECG in a dish"
ORIGIN OF THE FIELD POTENTIAL SIGNAL
When cardiomyocytes are cultured in MEA plates, spontaneous action potentials from a group of cells can be detected as fluctuations in the extracellular field potential at the adjacent recording electrode. The recorded cardiac field potential signal arises from the propagation of the cardiac action potential across the cell monolayer relative to the recording electrode. In this respect, the recorded field potential signal is analogous to the recorded ECG signal that measures changing voltage on the body surface induced by currents that propagate across the heart [A, B]. The field potential waveform comprises a sharp transient spike associated with Na+ influx and membrane depolarization (Halbach et al., 2003), followed by a shallower ramp during Ca2+ influx, ending with a repolarization wave that corresponds to K+ efflux. The field potential duration (FPD), the in vitro analog of the QT interval, measured from the initial Na+ spike to the maxima of the K+ repolarization wave, has been shown to correlate with action potential duration (APD) measurements in in vitro patch-clamp studies (Halbach et al., 2003) [C].
WHAT CAN YOU MEASURE?
Record key parameters of the cardiomyocyte activity.
FIELD POTENTIAL RECORDINGS
The Maestro system detects key parameters of cardiomyocyte activity, including depolarization, repolarization (FPD), beat timing and irregular beating (arrhythmia).
Proven most reliable cardiac assessment system in blinded, multi-national, FDA study.
COMPREHENSIVE PROARRHYTHMIA ASSAY (CiPA)
The aim of the Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative is to update the existing cardiac safety testing paradigm to better evaluate cardiovascular liability prior to clinical trials. What better forum to demonstrate the robustness of the Maestro cardiomyocyte assay? The CiPA team conclusively demonstrated the utility of a field potential-based human stem cell-derived cardiomyocyte assay to detect drug-induced arrhythmia effects. We are proud that the Maestro system played a pivotal role in the study.
BEST IN CLASS DATA
Most trusted. Most reliable. Fastest assay.
WHEN IT MATTERS, USE MAESTRO
Why did Maestro MEA users achieve the best data in the CiPA Myocyte Phase II study? It's not by chance. Axion have designed the Maestro MEA platform to be the complete solution for MEA hiPSC-cardiomyocyte assays. When it matters, use Maestro MEA.